|本期目录/Table of Contents|

[1]陈琪,施辉,戴立彬,等.氯氮平和齐拉西酮对精神分裂症患者体质量、血浆神经肽Y及瘦素影响的研究[J].医学研究与战创伤救治(原医学研究生学报),2016,18(02):142-144,150.[doi:10.3969/j.issn.1672-271X.2016.02.010]
　CHEN Qi,SHI Hui,DAI Li-bin,et al.Effect of clozapine and ziprasidone on body weight, neuropeptide Y and leptin of schizophrenia patients[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(02):142-144,150.[doi:10.3969/j.issn.1672-271X.2016.02.010]
点击复制

氯氮平和齐拉西酮对精神分裂症患者体质量、血浆神经肽Y及瘦素影响的研究()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第18卷
期数:
2016年02期
页码:
142-144,150
栏目:
出版日期:
2016-04-09

文章信息/Info

Title:
Effect of clozapine and ziprasidone on body weight, neuropeptide Y and leptin of schizophrenia patients
作者:
陈琪1; 施辉2; 戴立彬3; 程祺3; 李宁1; 徐乐平1; 宋梓祥3
1. 213003 江苏常州,解放军102医院精神二科;2. 325000 浙江温州，解放军113医院118临床部；3. 213003 江苏常州，解放军102医院少儿行为医学科
Author(s):
CHEN Qi1;  SHI Hui2; DAI Li-bin3;  CHENG Qi3;  LI Ning1;  XU Le-ping1;  SONG Zi-xinag3
1. Department of Psychiatry，102 Hospital of PLA， Changzhou, Jinagsu 213003， China; 2. 118 Clinical Branch, 113 Hospital of PLA, Wenzhou, Zhejiang 325000, China; 3. Departemnt of Adolescence and Childs Behavioral Medicine, 102 Hospital of PLA, Changzh
关键词:
氯氮平; 齐拉西酮; 神经肽Y; 瘦素; 精神分裂症
Keywords:
clozapine;  ziprasidone;  neuropeptide Y;  leptin;  schizophrenia
分类号:
R749.3
DOI:
10.3969/j.issn.1672-271X.2016.02.010
文献标志码:
A
摘要:
目的 分析比较氯氮平和齐拉西酮对精神分裂症患者体质量、血浆神经肽Y及瘦素的影响。方法 采用随机数表法，将60例符合《中国精神障碍分类与诊断标准》第3 版诊断标准的精神分裂症患者分为氯氮平组和齐拉西酮组， 每组各30例，分别接受氯氮平和齐拉西酮治疗，于治疗前、治疗第3、6周末，测定2组的体质量、血浆神经肽Y和瘦素水 平。结果 ① 氯氮平组治疗第3、6周末体质量和神经肽Y水平均显著高于治疗前，治疗第6周末瘦素水平显著高于治疗前（均P＜0.05）；齐拉西酮组治疗第3、6周末体质量、神经肽 Y和瘦素水平与治疗前比较差异无统计学意义(P＞0.05)；② 氯氮平组和齐拉西酮组体质量、神经肽Y和瘦素水平在组别×时间上存在明显的交互作用；③ 氯氮平组治疗3周和6周末 体质量的变化（△体质量）与神经肽Y的变化（△神经肽Y）呈明显正相关（r分别为0.662与0.495,均P＜0.05）；④ 逐步回归分析显示，氯氮平组△神经肽Y进入以△体质量为因变 量的回归方程，3周末△神经肽Y可以解释△体质量变异的41.9%，6周末△神经肽Y仍可以解释△体质量变异的21.8%。结论 与齐拉西酮比较，氯氮平显著增加了精神分裂症患者的体 质量，而神经肽Y的变化可能是氯氮平导致精神分裂症患者体质量增加的机制之一。
Abstract:
Objective To analyze and compare the effect of clozapine and ziprasidone treatment on body weight, neuropeptide Y and leptin in schizophrenics. Methods 60 patients who were eligible for the Classification and Diagnostic Criteria of Mental Disorders in China(3rd edition) were assigned to Clozapine and Ziprasidone treatment group respectively (30 patients for each group). Body weight, neuropeptide Y and leptin level of both groups were measured at baseline, weekend 3 and weekend 6. Results ①Both the body weight and plasma NPY level in clozapine group at weekend 3 and weekend 6 were significantly higher compared to the baseline, and leptin level was significantly higher at weekend 6 compared to baseline (P＞0.05). The difference of body weight and plasma NPY, leptin level at each time point in ziprasidone group were not statistically significant compared to the baseline (P＞0.05). ②There was significant interaction between groups and time of body weight, NPY, and leptin level in two groups. ③In clozapine group, the altering rate of body weight (△body weight) at weekend 3 and weekend 6 was positively correlated with that of NPY (△NPY) level (r=0.662, P＜0.05; r=0.495, P＜0.05). ④Stepwise regression analysis showed △plasma NPY of clozapine group entered to regression equation which the △body weight as dependent variable, and △plasma NPY can explain △body weight variance of 41.9% in 3 weekend, 21.8% in 6 weekend. Conclusion Clozapine significantly increases body weight in schizophrenia patients compared with Ziprasidone, and the change of neuropeptide Y may be the intrinsic cause of body weight increasing of patients.

参考文献/References:

[1]De Hert M,Detraux J,van Winkel R,et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs[J]. Nat Rev Endocrinol, 2012,8 (2): 114-126.
[2]Polyzos SA,Kountouras J,Zavos C,et al. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature[J]. J Clin Gastroenterol, 2011, 45(1): 50-54.
[3]Mercer RE，Chee MJ，Colmers WF．The role of NPY in hypothalamic mediated food intake[J]．Front Neuroendocrinol,2011,32(4):398-415．
[4]Pramyothin P,Khaodhiar L. Metabolic syndrome with the atypical antipsychotics [J]. Curr Opin Endocrinol Diabetes Obes, 2010, 17(5): 460-466.
[5]Das C,Mendez G,Jagasia S, et al. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysisof behavioral and pharmacologic treatments[J]. Ann Clin Psychiatry, 2012, 24(3): 225-239.
[6]Mc Evoy JP，Meyer JM，Goff DC, et al．Prevalence of the metabolic syndrome in patients with schizophrenia：baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness(CATIE) schizophrenia trial and comparison with national estimates from NHANESIII[J]．Schizophr Res,2005,80(1):19-32．
[7]张 本,王 丰,王学义,等．精神分裂症患者伴发代谢综合征的相关因素[J]．中国心理卫生杂志,2006,20(10):661-664．
[8]陈剑华,刘登堂,李 岩,等.氯氮平与代谢综合征的研究进展[J].上海交通大学学报（医学版）,2010,30(11):1424-1427.
[9]Wu RR，Zhao JP，Liu ZN，et al．Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia[J]. Psychopharmacology(Berl),2006,186(4):572-578．
[10]王恩霞,刘元华,李彩芳,等.非典型抗精神病药物对精神分裂症患者体重、糖脂代谢的影响[J].中国民康医学,2013,25(23):19-21.
[11]刘朝军,田素赢,宋光云,等.齐拉西酮对精神分裂症患者体质量、血糖和泌乳素的影响[J].神经疾病与精神卫生,2009,9(1):50-52.
[12]Lamberti JS，Olson D，Crilly JF,et al．Prevalence of the metabolic syndrome among patients receiving clozapine[J]．Am J Psychiatry,2006,163(7):1273-1276 ．
[13]Reynolds GP，Kirk SL．Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms[J]. Pharmacol Ther,2010,125(1):169-179．
[14]Supranowicz P，Wysocki MJ，Car J，et al．The risk of over-weight and obesity in chronic diseases among Warsaw inhabit ants measured by self-reported method[J]． Rocz Panstw ZaklHig，2013,64（2）：197-203．
[15]Zhang I ，Yagi M，Herzog H．The role of NPY and ghrelin in anorexia nervosa[J]．Curr Pharm Des，2012，18（22）：4766-4778.
[16]Nam SY，Kratzsch J，Kim KW,et al．Cerebrospinal fluid and plasma concentrations of leptin,NPY,and alpha-MSH in obese women and their relationship to negative energy balance[J]. J Clin Endocrinol Metab,200l,86(10):4849-4853.
[17]Shintani M, Ogawa Y，Ebihara K,et al．Ghrelin，an endogenous growth hormone secretagogue，is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway[J]. Diabetes,2001,50(2): 227-232.
[18]汪卫华,赵汉清,王焕林,等.氯氮平、利培酮、奥氮平、喹硫平和氟哌啶醇对首发精神分裂症患者血浆瘦素的影响[J].中国行为医学科学,2008,17(2):138-140.
[19]宋梓祥,陈 琪,徐乐平,等.氯氮平与氟哌啶醇对精神分裂症患者体质量和神经肽Y及瘦素的影响[J].中华精神科杂志,2012,45(6):331-334.
[20]王海林，杨 扬，蔡东联.营养宣教对舰艇超重或肥胖官兵的影响[J].东南国防医药,2014,16(3):295-297.
[21]吴 刚,董春霞,黄少南,等.运动疗法对抗精神病药物所致精神分裂症患者糖代谢异常的干预研究[J].东南国防医药,2012,14(4):339-341.

相似文献/References:

[1]杨雅玲,刘华斌,林庆金.枸橼酸坦度螺酮治疗帕金森病异动症的疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2021,23(02):146.[doi:10.3969/j.issn.1672-271X.2021.02.008]
　YANG Ya-ling,LIU Hua-bin,LIN Qing-jin.Therapeutic effect of tandorone citrate on Parkinson’s disease[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(02):146.[doi:10.3969/j.issn.1672-271X.2021.02.008]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2016-03-20